From interpretable NT-proBNP prediction to equitable laboratory stewardship

Dear Editor,

Ishida et al. ¹ deserve particular commendation for delivering an elegant and highly relevant advance in contemporary laboratory medicine: an interpretable routine-laboratory-data model for stratifying the likelihood of elevated NT-proBNP, successfully integrated into diagnostic support middleware. At a time when healthcare systems seek innovations that are accurate, transparent, and immediately deployable, their study is exemplary in translating routinely generated biochemical data into clinically actionable intelligence. Importantly, the work positions artificial intelligence not as a replacement for expert laboratory practice, but as a pragmatic extension of it – enhancing test stewardship, prioritisation, and timely cardiovascular risk recognition. Such clinically anchored innovation is precisely the type of translational progress that strengthens the global impact of Annals of Clinical Biochemistry, where advances are most valuable when they improve patient care through intelligent use of laboratory science.

The finding is especially promising because NT-proBNP remains integral to the early diagnosis, prognostic assessment, and management of heart failure, yet access to natriuretic peptide testing continues to vary substantially across healthcare systems. ² Recent population-level evidence suggests that socioeconomically disadvantaged patients may experience lower rates of outpatient natriuretic peptide testing despite carrying a disproportionate burden of cardiovascular risk. ³ In this context, a transparent model derived from universally available routine laboratory parameters could become more than a predictive tool – it could serve as an equity-enabling triage mechanism, helping laboratories prioritise confirmatory NT-proBNP testing for patients most likely to benefit. If responsibly implemented, such an approach may reduce diagnostic delay, optimise resource utilisation, and extend the clinical reach of advanced biomarker strategies to settings where direct access remains limited.

However, the next step should be cautious translation rather than premature generalisation. We propose a laboratory AI stewardship framework with five components: multicentre external validation across assay platforms; calibration monitoring after implementation; subgroup performance auditing in older adults, women, renal impairment, and under-represented populations; decision-curve analysis linked to downstream NT-proBNP ordering; and transparent reporting using TRIPOD + AI and DECIDE-AI principles.^4,5 Such a pathway would shift evaluation from algorithmic accuracy alone to clinical safety, diagnostic yield, and equitable access.

Future research should test whether this middleware reduces missed heart failure diagnoses, unnecessary testing, clinician alert fatigue, and delays in specialist referral. Importantly, implementation studies should measure false-negative consequences, clinician override patterns, and cost-effectiveness in both high-resource and resource-constrained settings. The real innovation of Ishida et al. ¹ is therefore not only the decision tree, but the possibility of transforming routine clinical biochemistry into a globally scalable, ethically auditable diagnostic infrastructure. This letter aims to support that transition from interpretable prediction to equitable, patient-centred laboratory stewardship.